



Clinical Advances in Interstitial Lung Diseases

Guest Editors:

Dr. Yoshiaki Zaizen

Division of Respiriology,
Neurology and Rheumatology,
Department of Medicine, Kurume
University School of Medicine, 67
Asahi-machi, Kurume, Fukuoka
830-0011, Japan

Dr. Masaki Okamoto

Division of Respiriology,
Neurology and Rheumatology,
Department of Medicine, Kurume
University School of Medicine, 67
Asahi-machi, Kurume, Fukuoka
830-0011, Japan

Deadline for manuscript
submissions:
closed (20 November 2024)

Message from the Guest Editors

Dear Colleagues,

The field of interstitial lung disease has experienced significant progress over the past decade. The cryobiopsy method has been established as a method for obtaining tissue samples for the pathology. With the improvement of analysis technology using artificial intelligence, there have also been remarkable developments in genome classification. In pharmacological therapy, two antifibrotic agents, pirfenidone and nintedanib, have provided alternatives to conventional corticosteroid-based anti-inflammatory therapy and are effective in the treatment of idiopathic and progressive pulmonary fibrosis. Additionally, today, many compounds with antifibrotic activity are in development. Scientific evidence is also slowly but surely establishing non-pharmacological therapies, such as respiratory rehabilitation. We now need to understand the pathophysiology and prognoses of patients with interstitial lung disease and provide appropriate treatment and management.

We welcome authors to submit papers that will provide more reliable evidence of the advances in the diagnosis and treatment of interstitial lung disease.

Dr. Yoshiaki Zaizen
Dr. Masaki Okamoto
Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care
Medicine, University of Tokyo,
Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)